Abstract
Fentanyl is a potent opioid with a short duration of action. Fentanyl sublingual has been formulated as a rapidly disintegrating tablet that is quickly absorbed, producing a fast onset of analgesia.
In two randomized, double-blind clinical trials, fentanyl sublingual as single fixed or titrated doses reduced pain intensity during breakthrough pain episodes to a significantly greater extent than placebo in opioid-tolerant cancer patients.
In a fixed-dose phase II trial and a titrated-dose phase III trial, fentanyl sublingual (as a single 400 μg dose and as titrated doses) reduced mean pain intensity difference (PID) to a significantly greater extent than placebo over the entire treatment period (up to 60 minutes), reaching statistical significance 15 minutes post-dose.
In the titrated-dose study, the mean sum of PID (area under the PID vs time curve) at 30 minutes post-dose was significantly greater with fentanyl sublingual than placebo, with significant improvements in PID seen at 10 minutes maintained at 60 minutes post-dose.
In the phase III study, patients receiving fentanyl sublingual were more satisfied with their treatment than patients receiving placebo (measured using the Patient Global Evaluation of Medication score), and almost half of all fentanyl sublingual recipients were satisfied or very satisfied with their treatment.
Fentanyl sublingual was generally well tolerated in the two trials and most adverse events were mild to moderate in intensity.
Similar content being viewed by others
References
Portenoy RK, Payne D, Jacobsen P. Breakthrough pain: characteristics and impact in patients with cancer pain. Pain 1999 May; 81(1–2): 129–34
Fine PG. Breakthrough cancer pain: epidemiology, characteristics and management. CNS Drugs 2000 May; 13: 313–9
Miaskowski C, Cleary J, Burney R, et al. American Pain Society guideline for the management of cancer pain in adults and children [online]. Available from URL: http://www.guidelines.gov/summary/summary.aspx?doc_id=7297 [Accessed 2010 Oct 11]
Scottish Intercollegiate Guidelines Network. Control of pain in adults with cancer [online]. Available from URL: http://www.sign.ac.uk/pdf/qrg106.pdf [Accessed 2010 Oct 11]
Portenoy RK, Lesage P. Management of cancer pain. Lancet 1999 May 15; 353(9165): 1695–700
Mercadante S, Fulfaro F. World Health Organization guidelines for cancer pain: a reappraisal. Ann Oncol 2005 May; 16 Suppl.: iv132–5
Hanks GW, de Conno F, Cherny N, et al. Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br J Cancer 2001 Mar 2; 84(5): 587–93
Davies AN, Dickman A, Reid C, et al. The management of cancer-related breakthrough pain: recommendations of a task group of the science committee of the association for palliative medicine of Great Britain and Ireland. Eur J Pain 2009 Apr; 13(4): 331–8
Christrup LL, Lundorff L, Werner M. Novel formulations and routes of administration for opioids in the treatment of breakthrough pain. Therapy 2009; 6(5): 695–706
Blick SKA, Wagstaff AJ. Fentanyl buccal tablet: in breakthrough pain in opioid-tolerant patients with cancer. Drugs 2006; 66(18): 2387–93
William L, MacLeod R. Management of breakthrough pain in patients with cancer. Drugs 2008; 68(7): 913–24
Grape S, Schug SA, Lauer S, et al. Formulations of fentanyl for the management of pain. Drugs 2010; 70(1): 57–72
Electronic Medicines Compendium. Abstral sublingual tablets: summary of product characteristics [online]. Available from URL: http://emc.medicines.org.uk/medicine/21371/SPC/Abstral+Sublingual+Tablets/ [Accessed 2010 Oct 11]
ProStrakan Group. ProStrakan announces FDA acceptance of Abstral filing [media release]. 2009 Oct 6
Jeal W, Benfield P. Transdermal fentanyl: a review of its pharmacological properties and therapeutic efficacy in pain control. Drugs 1997; 53(1): 109–38
Muijsers RBR, Wagstaff AJ. Transdermal fentanyl: an updated review of its pharmacological properties and therapeutic efficacy in chronic cancer pain control. Drugs 2001; 61(15): 2289–307
Hair PI, Keating GM, McKeage K. Transdermal matrix fentanyl membrane patch (Matrifen®): in severe cancer-related chronic pain. Drugs 2008; 68(14): 2001–9
Narita M, Imai S, Itou Y, et al. Possible involvement of μ1-opioid receptors in the fentanyl- or morphine-induced antinociception at supraspinal and spinal sites. Life Sci 2002 Apr 5; 70(20): 2341–54
Maguire P, Tsai N, Kamal J, et al. Pharmacological profiles of fentanyl analogs at mu, delta and kappa opiate receptors. Eur J Pharmacol 1992 Mar 24; 213(2): 219–25
Bilfinger TV, Fimiani C, Stefano GB. Morphine’s immunoregulatory actions are not shared by fentanyl. Int J Cardiol 1998 Apr; 64 Suppl. 1: 61–6
Rosow CE, Moss J, Philbin DM, et al. Histamine release during morphine and fentanyl anesthesia. Anesthesiology 1982; 56(2): 93–6
Bovill JG. Which potent opioid? Important criteria for selection. Drugs 1987; 33: 520–30
Megens AAHP, Artois K, Vermeire J, et al. Comparison of the analgesic and intestinal effects of fentanyl and morphine in rats. J Pain Symptom Manage 1998; 15(4): 253–7
Bredenberg S, Duberg M, Lennernas B, et al. In vitro and in vivo evaluation of a new sublingual tablet system for rapid oromucosal absorption using fentanyl citrate as the active substance. Eur J Pharm Sci 2003; 20(3): 327–34
Lennernas B, Frank-Lissbrant I, Lennernas H, et al. Sublingual administration of fentanyl to cancer patients is an effective treatment for breakthrough pain: results from a randomised phase II study. Palliat Med 2010 Apr; 24: 286–93
Williams DA, Foye WO, Lemke TL. Foye’s principles of medicinal chemistry. 5th ed. Baltimore (MD): Lippincott Williams and Wilkins, 2002
Lennernas B, Hedner T, Holmberg M, et al. Pharmacokinetics and tolerability of different doses of fentanyl following sublingual administration of a rapidly dissolving tablet to cancer patients: a new approach to treatment of incident pain. Br J Clin Pharmacol 2005 Feb; 59(2): 249–53
Lorch U, Farrell F, Kilborn J, et al. Pharmacokinetics and tolerability of sublingual fentanyl in healthy Japanese and Caucasian volunteers: phase I, open-label single-dose study. Proceedings of the 13th International Pain Clinic Congress; 2008 May 29–Jun 1; Seoul, 131–5
Rauck RL, Tark M, Reyes E, et al. Efficacy and long-term tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain. Curr Med Res Opin 2009 Oct 8; 25(12): 2877–85
Zeppetella G. Sublingual fentanyl citrate for cancer-related breakthrough pain: a pilot study. Palliat Med 2001 Jul; 15(4): 323–8
Danjoux C, Franssen E, Chow E, et al. Sublingual fentanyl citrate for control of breakthrough pain in patients referred for palliative radiotherapy. Curr Oncol 2004; 11(1): 3–7
Nalamachu S, Howell J, Derrick R. Long-term safety and tolerability of sublingual fentanyl [poster]. American Academy of Pain Medicine 25th Annual Meeting; 2009 Jan 28–31; Honolulu (HI)
Acknowledgements and Disclosures
The manuscript was reviewed by: H. Lennernäs, Department of Pharmacy, Uppsala University, Uppsala, Sweden; S. Mercadante, Department of Pain Relief and Palliative Care, La Maddalena Cancer Center, Palermo, Italy.
The preparation of this review was not supported by any external funding. During the peer review process, the manufacturer of the agent under review was also offered an opportunity to comment on this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Chwieduk, C.M., McKeage, K. Fentanyl Sublingual. Drugs 70, 2281–2288 (2010). https://doi.org/10.2165/11200910-000000000-00000
Published:
Issue Date:
DOI: https://doi.org/10.2165/11200910-000000000-00000